In particular, it has recently been suggested that overexpression of the HER2 protein may be observed in approximately 25–30% of endometrial serous carcinomas, which are typically p53-mutated and therefore could constitute a potential therapeutic target (by analogy with the treatment regimen already applied in breast cancer) [10,11]. This evidence concerns the gene TP53 and breast carcinoma.